MGTX
MeiraGTx Holdings plc
$9.59
-0.10%
$888.1M
No data for this timeframe.
Vol
Market Cap$888.1M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Insider Activity0B / 4S
Insider Net $-$1.9M
SEC Reports7
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001735438·Prev Close $9.60
Recent Activity
Jun 10, 2026
Insider
Harris Keith R. acquired via exercise 75,000 shares
Director
May 27, 2026
Insider
Giroux Richard gifted 7,000 shares
CFO & COO
May 20, 2026
SEC
CEO Alexandria Forbes filed a Form 144 to sell 62,000 ordinary shares with an estimated value of $568,540, representing
144 — Impact 3/10
May 19, 2026
Insider
Forbes Alexandria sold 62,000 shares
PRESIDENT & CEO @ $9.17 ($568.5K)
May 14, 2026
other
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a v
May 14, 2026
SEC
MeiraGTx reported Q1 2026 results with a net loss of $46.3M ($0.57/share) vs $40.0M ($0.51/share) a year ago, while tota
8-K — Impact 7/10
May 14, 2026
SEC
MeiraGTx reported Q1 2026 EPS of $0.19, a 142% beat vs consensus of -$0.45, on revenue of $0.3M (well below the $17.0M c
PRESS-RELEASE — Impact 7/10
Apr 16, 2026
Press
MeiraGTx has reacquired global rights to botaretigene sparoparvovec (bota-vec) for XLRP from Johnson & Johnson for a $25
Impact 7/10
Price Targets
$28.25
+194.6% upside
Strong Buy
Current $9.59
Low $19.00
Median $26.00
High $50.00
8 analysts
$19.00
$50.00
Analyst Ratings
4Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Apr 22, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Apr 17, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Apr 1, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
| Mar 27, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.25 ▲ +62.6% | $-0.60 — $0.45 | 5 | |
| Next Q | $-0.50 ▲ +19.7% | $-0.62 — $-0.29 | 19% YoY | 5 |
| Current FY | $-1.47 ▲ +28.5% | $-2.44 — $-0.52 | -3% YoY | 6 |
| Next FY | $-1.39 ▲ +8.3% | $-2.50 — $0.67 | 5% YoY | 6 |
Latest Reports
NEUTRAL
144
3/10
CEO Alexandria Forbes filed a Form 144 to sell 62,000 ordinary shares with an estimated value of $568,540, representing
May 20, 2026
BULLISH
8-K
7/10
MeiraGTx reported Q1 2026 results with a net loss of $46.3M ($0.57/share) vs $40.0M ($0.51/share) a year ago, while tota
May 14, 2026
BULLISH
Press
7/10
MeiraGTx has reacquired global rights to botaretigene sparoparvovec (bota-vec) for XLRP from Johnson & Johnson for a $25
Apr 16, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Harris Keith | M | $0.00 |
| May 27, 2026 | Giroux Richard | G | $0.00 |
| May 19, 2026 | Forbes Alexandria | SELL | $568.5K |
| May 13, 2026 | Fleck Penny | A | $0.00 |
| May 13, 2026 | Fleck Penny | A | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
8 unique insiders with 23 transactions. Net insider value: -$1.9M ($0.00 bought, $1.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Harris Keith R. | Director | EXERCISE | 75,000 | — | — |
| May 27, 2026 | Giroux Richard | CFO & COO | GIFT | 7,000 | — | — |
| May 19, 2026 | Forbes Alexandria | PRESIDENT & CEO | SELL | 62,000 | $9.17 | $568.5K |
| May 13, 2026 | Fleck Penny Renee | CHIEF DEVELOPMENT OFFICER | AWARD | 100,000 | — | — |
| May 13, 2026 | Fleck Penny Renee | CHIEF DEVELOPMENT OFFICER | AWARD | 100,000 | — | — |
| Apr 21, 2026 | Giroux Richard | CFO & COO | SELL | 56,000 | $10.22 | $572.3K |
| Apr 17, 2026 | PERCEPTIVE ADVISORS LLC | Director | AWARD | 555,555 | $9.00 | $5.0M |
| Apr 7, 2026 | Naylor Stuart | CHIEF DEV. OFFICER | SELL | 27,661 | $9.36 | $258.9K |
| Mar 25, 2026 | PERCEPTIVE ADVISORS LLC | Director | AWARD | 400,000 | — | — |
| Mar 25, 2026 | PERCEPTIVE ADVISORS LLC | Director | D | 400,000 | — | — |
| Mar 24, 2026 | Forbes Alexandria | PRESIDENT & CEO | SELL | 62,000 | $7.41 | $459.4K |
| Feb 21, 2026 | Naylor Stuart | CHIEF DEV. OFFICER | EXERCISE | 25,000 | — | — |
| Feb 21, 2026 | Naylor Stuart | CHIEF DEV. OFFICER | TAX W/H | 11,750 | $7.45 | $87.5K |
| Feb 21, 2026 | Giroux Richard | CFO & COO | EXERCISE | 60,000 | — | — |
| Feb 21, 2026 | Giroux Richard | CFO & COO | TAX W/H | 31,726 | $7.45 | $236.4K |
| Feb 21, 2026 | Forbes Alexandria | PRESIDENT & CEO | EXERCISE | 62,500 | — | — |
| Feb 21, 2026 | Forbes Alexandria | PRESIDENT & CEO | TAX W/H | 33,048 | $7.45 | $246.2K |
| Feb 21, 2026 | Zeldin Robert K | CHIEF MEDICAL OFFICER | EXERCISE | 7,500 | — | — |
| Feb 21, 2026 | Zeldin Robert K | CHIEF MEDICAL OFFICER | TAX W/H | 2,952 | $7.45 | $22.0K |
| Feb 21, 2026 | Wollin Robert J | GENERAL COUNSEL AND SECRETARY | EXERCISE | 11,250 | — | — |
| Feb 21, 2026 | Wollin Robert J | GENERAL COUNSEL AND SECRETARY | TAX W/H | 5,949 | $7.45 | $44.3K |
| Jan 7, 2026 | Zeldin Robert K | CHIEF MEDICAL OFFICER | TAX W/H | 7,814 | $7.73 | $60.4K |
| Aug 2, 2022 | PERCEPTIVE ADVISORS LLC | Director | AWARD | 400,000 | — | — |
7 SEC filing reports analyzed. Sentiment: 5 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 6.4/10.
NEUTRAL
144
3/10
CEO Alexandria Forbes filed a Form 144 to sell 62,000 ordinary shares with an estimated value of $56
May 20, 2026
BULLISH
8-K
7/10
MeiraGTx reported Q1 2026 results with a net loss of $46.3M ($0.57/share) vs $40.0M ($0.51/share) a
May 14, 2026
BULLISH
PRESS-RELEASE
7/10
MeiraGTx reported Q1 2026 EPS of $0.19, a 142% beat vs consensus of -$0.45, on revenue of $0.3M (wel
May 14, 2026
BULLISH
8-K
7/10
MeiraGTx has entered into a strategic collaboration with Hologen to co-develop and commercialize gen
Apr 24, 2026
NEUTRAL
8-K, 424B5
6/10
MeiraGTx Holdings plc (MGTX) entered into an underwriting agreement to sell 11,111,111 ordinary shar
Apr 16, 2026
BULLISH
8-K
8/10
MeiraGTx reacquired the gene therapy candidate botaretigene sparoparvovec (bota-vec) for X-linked re
Apr 16, 2026
BULLISH
8-K
7/10
MeiraGTx announced positive 3-year durability data from its Phase 1 AQUAx clinical trial of AAV-hAQP
Apr 16, 2026
BULLISH
7/10
MeiraGTx has reacquired global rights to botaretigene sparoparvovec (bota-vec) for XLRP from Johnson
Apr 16, 2026
BULLISH
8/10
MeiraGTx announced positive three-year durability data from its Phase 1 AQUAx trial of AAV-hAQP1 for
Apr 16, 2026
MIXED
7/10
MeiraGTx reported financial results for 2025, highlighted by a significant decline in service revenu
Mar 26, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 4 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$28.25 mean target
+194.6% upside
Strong Buy (3.00)
$19.00 Low
$50.00 High
| Metric | Value |
|---|---|
| Current Price | $9.59 |
| Target Low | $19.00 |
| Target Mean | $28.25 |
| Target Median | $26.00 |
| Target High | $50.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.25 | $-0.60 | $0.45 | — | +62.6% | 3↑ 1↓ | $0.0B | 477.7% | 5 |
| Next Q 2026-09-30 |
$-0.50 | $-0.62 | $-0.29 | 19.4% | +19.7% | 3↑ 0↓ | $0.0B | 1311.6% | 5 |
| Current FY 2026-12-31 |
$-1.47 | $-2.44 | $-0.52 | -3.3% | +28.5% | 3↑ 0↓ | $0.0B | -39.4% | 6 |
| Next FY 2027-12-31 |
$-1.39 | $-2.50 | $0.67 | 5.1% | +8.3% | 4↑ 0↓ | $0.1B | 97.5% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.248 | |
| 7d ago | $-0.268 | +0.020 |
| 30d ago | $-0.662 | +0.414 |
| 60d ago | $-0.760 | +0.512 |
| 90d ago | $-0.625 | +0.377 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 22, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Apr 17, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 1, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Mar 27, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Mar 27, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
other
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medic
May 14, 2026
earnings
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
<p>LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medic
May 13, 2026
earnings_calendar
MGTX Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
MGTX Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
earnings_calendar
MGTX Q1 2026 Earnings Scheduled — 2026-05-07
Apr 17, 2026
short_interest
FTD: MGTX — 331,744 shares ($3.1M) failed to deliver
Settlement: 20260417, Price: $9.48, FTD Value: $3,144,933.12, MEIRAGTX HLDGS PLC (CYM)
Apr 16, 2026
other
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
<p align="justify">LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-s
Apr 16, 2026
m_and_a
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
<p>LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic med
Apr 16, 2026
fda
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
<p>LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic med
Apr 14, 2026
other
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
<p align="center"><em>- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study</em></p>
Apr 7, 2026
short_interest
FTD: MGTX — 52,932 shares ($0.5M) failed to deliver
Settlement: 20260407, Price: $9.52, FTD Value: $503,912.64, MEIRAGTX HLDGS PLC (CYM)
Mar 27, 2026
short_interest
FTD: MGTX — 132,774 shares ($1.0M) failed to deliver
Settlement: 20260327, Price: $7.53, FTD Value: $999,788.22, MEIRAGTX HLDGS PLC (CYM)
Mar 26, 2026
earnings
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
<p>LONDON and NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic med
Mar 12, 2026
earnings_calendar
MGTX Q4 2025 Earnings After Market Close — 2026-03-12
Mar 11, 2026
earnings_calendar
MGTX Q4 2025 Earnings After Market Close — 2026-03-11